Men can have more confidence in the results of the special test cPSA for prostate cancer than those of conventional testing, according to the findings of a study which have now been published in the renowned Journal of Urology (Vol. 175 (4), 1275-1280, April 2006).

The test, available from Bayer HealthCare, is used to determine the concentration of complexed Prostate-Specific Antigen (cPSA) in blood samples. This protein is produced in the prostate and excreted into the bloodstream in particularly high levels in men suffering from prostate cancer. The conventional method measures total PSA (tPSA). However, the prostate also produces increased quantities of tPSA when, for example, the patient has benign prostate enlargement, while the cPSA level is less strongly affected in this case.

This study compared the two methods. The results showed that the cPSA test discovered more men with a high risk of cancer. In addition, the scientists calculated that using the cPSA test instead of the tPSA test made it possible to reduce the number of required biopsies by more than 10%. According to the study results, a man with an elevated level of cPSA but normal level of tPSA was twice as likely to have prostate cancer as a man with an elevated level of tPSA and normal level of cPSA.

This means that the cPSA test offers a superior preselection regarding those patients from whom it would be appropriate to take a biopsy, note the scientists. They therefore recommend that the cPSA test be used as the first-line test for diagnosing prostate cancer.

Prostate cancer, with approximately 40,000 new cases per year, is the most common form of cancer in men in Germany. Men have a 17 percent risk of contracting prostate cancer in their lives. The risk is twice as high if the father or an uncle suffered from this form of cancer. If the carcinoma is restricted to the prostate itself, the chances of a cure are 85 to 100 percent.

The German Urology Association recommends that cancer screening should be conducted every year in all men aged above 50. Early recognition measures should be brought forward to age 45 if there is a familial predisposition. Despite the excellent prospects of a cure, only 12 percent of those entitled to do so take advantage of the cancer screening available from their urologist.

Bayer HealthCare

Bayer HealthCare, a subsidiary of Bayer AG, is one of the world's leading, innovative companies in the health care and medical products industry based in Leverkusen/Germany. In 2005, the Bayer HealthCare subgroup generated sales amounting to some 9.4 billion Euro. Bayer HealthCare employed 33.800 people worldwide in 2005.

The company combines the global activities of the divisions Animal Health, Consumer Care, Diabetes Care, Diagnostics and Pharmaceuticals. Since January 1, 2006 the new Pharmaceutical Division consists of the former Biological Products and Pharmaceutical Division and now comprises three business units: Hematology/Cardiology, Oncology and Primary Care.

Bayer HealthCare's aim is to discover and manufacture products that will improve human and animal health worldwide. The products enhance well-being and quality of life by diagnosing, preventing and treating diseases.

Bayer HealthCare

Tag Cloud